Gaucher Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Gaucher Disease stocks.

Gaucher Disease Stocks Recent News

Date Stock Title
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Jul 2 SNY Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
Jun 29 SNY Where Will Novavax Be in 1 Year?
Jun 28 SNY PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Jun 28 SNY 3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
Jun 27 SNY Vigil Neuroscience jumps 34% as Sanofi invests $40M
Jun 27 SNY Formation Bio secures $372m funds for AI-driven drug platform
Jun 27 SNY Sanofi reports positive data from Phase III EoE treatment trial
Gaucher Disease

Gaucher's disease or Gaucher disease () (GD) is a genetic disorder in which glucocerebroside (a sphingolipid, also known as glucosylceramide) accumulates in cells and certain organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet count and enlargement of the liver and spleen, and is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as glucosylceramidase), which acts on glucocerebroside. When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells and especially in macrophages (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain, and bone marrow.
Manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders or bone lesions that may be painful, severe neurological complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelet count, and yellow fatty deposits on the white of the eye (sclera). Persons seriously affected may also be more susceptible to infection. Some forms of Gaucher's disease may be treated with enzyme replacement therapy.
The disease is caused by a recessive mutation in the GBA gene located on chromosome 1 and affects both males and females. About one in 100 people in the United States are carriers of the most common type of Gaucher disease. The carrier rate among Ashkenazi Jews is 8.9% while the birth incidence is one in 450.Gaucher's disease is the most common of the lysosomal storage diseases. It is a form of sphingolipidosis (a subgroup of lysosomal storage diseases), as it involves dysfunctional metabolism of sphingolipids.The disease is named after the French physician Philippe Gaucher, who originally described it in 1882.

Browse All Tags